$MGTX

Goldman Sachs initiated coverage on MeiraGTx (MGTX) with a Neutral rating and $16.00 price target, up from $11.75. The company focuses on gene therapies for retinal diseases, xerostomia, and Parkinson’s. Analysts expect profitability this year. MeiraGTx secured a $400M investment deal with Oberland Capital, including capped royalties and equity. Other analysts maintain Buy ratings with higher price targets.

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, tod

Forbes Alexandria (PRESIDENT & CEO) sold 62,000 shares of MeiraGTx Holdings plc (MGTX) at $13.86 ($0.86M total) on 2026-08-18 under a Rule 10b5-1 trading plan.

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe

Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $12.51 ($0.70M total) on 2026-07-21 under a Rule 10b5-1 trading plan.

MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.

MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 mgtx-20260630xex10d1.htm EX-10.1 Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. ​ Execution Version ​ ​ ROYALTY NOTE PUR

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MeiraGTx Holdings plc_June 11, 2026 0001735438 false 0001735438 2026-06-11 2026-06-11 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of

MeiraGTx Holdings is a gene therapy specialist focused on inherited retinal diseases and neurology, operating a vertically integrated platform with its own manufacturing facilities. CEO Alexandria Forbes recently sold 62,000 shares, adding to the stock's volatility. Despite the insider sale, the company's long-term value is expected to be driven primarily by progress in clinical trials, regulatory milestones, and collaboration advancements.